Adaptimmune Therapeutics PLC Insider Trading Activity
Every SEC Form 4 insider transaction reported for Adaptimmune Therapeutics PLC (ADAPY), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ADAPY insiders buying or selling?
Adaptimmune Therapeutics PLC insiders reported no open-market purchases or sales in the last 12 months. Since March 2018, Trabud has recorded 142 Form 4 filings for ADAPY: 44 buys ($390.4M) and 98 sells ($47.7M).
Source: SEC EDGAR Form 4
Key Statistics (March 2018 – Sep 3, 2025)
Total Form 4 filings
142
SEC EDGAR
Insider filers
26
Insider buys (44)
$390.4M
Insider sells (98)
$47.7M
Insider sentiment
Net buyingNet insider flow of $342.6M in net buying since March 2018.
Recent ADAPY insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 3, 2025 | Gavin Wood | Chief Financial Officer | Sale | 96.0K | $0.01 | $950.4 | SEC ↗ |
| Aug 29, 2025 | William C Bertrand JR | Chief Operating Officer | Sale | 207.0K | $0.01 | $2.1K | SEC ↗ |
| Aug 19, 2025 | Ali Behbahani | Director | Sale | 19.5M | $0.01 | $229.2K | SEC ↗ |
| Jul 30, 2025 | EcoR1 Capital, LLC | 10% Owner | Sale | 64.1M | $0.11 | $6.9M | SEC ↗ |
| Jan 18, 2025 | Elliot Norry | Chief Medical Officer | Sale | 5.6K | $0.58 | $3.2K | SEC ↗ |
| Jan 18, 2025 | John Lunger | Chief Patient Supply Officer | Sale | 5.6K | $0.58 | $3.2K | SEC ↗ |
| Jan 18, 2025 | William C Bertrand JR | Chief Operating Officer | Sale | 5.6K | $0.58 | $3.2K | SEC ↗ |
| Jan 18, 2025 | Adrian Rawcliffe | Chief Executive Officer | Sale | 30.6K | $0.58 | $17.8K | SEC ↗ |
| Jan 15, 2025 | Adrian Rawcliffe | Chief Executive Officer | Sale | 59.6K | $0.58 | $34.6K | SEC ↗ |
| Jan 15, 2025 | Cintia Piccina | Chief Commercial Officer | Sale | 13.0K | $0.57 | $7.5K | SEC ↗ |
| Jan 15, 2025 | Elliot Norry | Chief Medical Officer | Sale | 22.2K | $0.58 | $12.9K | SEC ↗ |
| Jan 15, 2025 | John Lunger | Chief Patient Supply Officer | Sale | 19.5K | $0.58 | $11.4K | SEC ↗ |
| Jan 15, 2025 | William C Bertrand JR | Chief Operating Officer | Sale | 19.5K | $0.58 | $11.4K | SEC ↗ |
| Jun 18, 2024 | Cintia Piccina | Chief Commercial Officer | Sale | 24.5K | $0.93 | $22.8K | SEC ↗ |
| Jan 17, 2024 | Adrian Rawcliffe | Chief Executive Officer | Sale | 39.4K | $0.70 | $27.6K | SEC ↗ |
| Jan 17, 2024 | Elliot Norry | Chief Medical Officer | Sale | 20.6K | $0.69 | $14.1K | SEC ↗ |
| Jan 17, 2024 | John Lunger | Chief Patient Supply Officer | Sale | 22.8K | $0.70 | $15.9K | SEC ↗ |
| Jan 17, 2024 | William C Bertrand JR | Chief Operating Officer | Sale | 23.6K | $0.70 | $16.4K | SEC ↗ |
| Jan 12, 2024 | Elliot Norry | Chief Medical Officer | Sale | 11.8K | $0.85 | $10.0K | SEC ↗ |
| Jan 12, 2024 | William C Bertrand JR | Chief Operating Officer | Sale | 9.2K | $0.85 | $7.8K | SEC ↗ |
| Jan 12, 2024 | Adrian Rawcliffe | Chief Executive Officer | Sale | 29.2K | $0.85 | $24.7K | SEC ↗ |
| Jan 12, 2024 | John Lunger | Chief Patient Supply Officer | Sale | 9.2K | $0.85 | $7.8K | SEC ↗ |
| Sep 1, 2023 | Adrian Rawcliffe | Chief Executive Officer | Sale | 2.4K | $0.78 | $1.9K | SEC ↗ |
| Aug 1, 2023 | John Lunger | Chief Patient Supply Officer | Sale | 3.1K | $0.91 | $2.8K | SEC ↗ |
| Jul 10, 2023 | Garry E Menzel | Director | Sale | 47.7K | $0.91 | $43.4K | SEC ↗ |
Showing the 25 most recent of 142 Form 4 filings for Adaptimmune Therapeutics PLC.
Most active ADAPY insiders
- Adrian Rawcliffe24 filings
- John Lunger20 filings
- William C Bertrand JR17 filings
- Elliot Norry13 filings
- Anthony A. Florence Jr.4 filings
Ask anything about ADAPY insider activity
Use Trabud's AI agent to query Adaptimmune Therapeutics PLC's Form 4 history in plain English — "Show me ADAPY CEO purchases this year" or compare it against any other ticker.
Open the AI agentADAPY insider trading FAQ
Are Adaptimmune Therapeutics PLC insiders buying or selling?
Adaptimmune Therapeutics PLC insiders reported no open-market purchases or sales in the last 12 months. Since March 2018, Trabud has recorded 142 Form 4 filings for ADAPY: 44 buys ($390.4M) and 98 sells ($47.7M). Over the full record that is net buying of $342.6M.
How many insiders trade ADAPY stock?
26 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Adaptimmune Therapeutics PLC. The most recent filing was accepted on Sep 3, 2025.
Where does Trabud get ADAPY insider trading data?
All ADAPY insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.